Lexeo Therapeutics (LXEO) Stock Price, News & Analysis

Company Overview

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a clinical-stage biotechnology company developing genetic medicines for serious diseases with limited treatment options. The company uses adeno-associated virus (AAV) vectors and other gene therapy technologies to deliver genetic material intended to address underlying causes of disease, with a focus on conditions affecting the central nervous system and cardiovascular system.

Lexeo’s pipeline includes LX2006, an investigational gene therapy being developed for Friedreich’s ataxia cardiomyopathy, a potentially life-threatening cardiac complication of Friedreich’s ataxia. The company is also advancing LX1001, an investigational therapy designed to address APOE4-associated Alzheimer’s disease, as well as programs targeting genetically defined cardiovascular diseases, including conditions involving PKP2-related arrhythmogenic cardiomyopathy.

Lexeo conducts its research and clinical development activities primarily in the United States and works with academic and clinical institutions to advance its programs. The company was founded to develop genetic medicines for diseases driven by specific genetic abnormalities and is headquartered in New York. Its executive leadership is headed by Chief Executive Officer R. Nolan Townsend.

Key Stats

• Today's Range: $2.63 to $2.84
• 50-Day Range: $2.63 to $5.37
• 52-Week Range: $2.56 to $10.99
• Volume: 2.51 million shs
• Average Volume: 2.07 million shs
• Market Capitalization: $216.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.43
• Consensus Rating: Buy

Lexeo Therapeutics Stock Analysis - MarketRank™

Lexeo Therapeutics scored higher than 78% of companies evaluated by MarketBeat, and ranked 123rd out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Buy

Consensus Rating

Lexeo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Lexeo Therapeutics has a consensus price target of $16.43, representing about 522.3% upside from its current price of $2.64.

Amount of Analyst Coverage

Lexeo Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Lexeo Therapeutics are expected to decrease in the coming year, from ($1.18) to ($1.44) per share.

Price to Book Value per Share Ratio

Lexeo Therapeutics has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

23.94% of the float of Lexeo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lexeo Therapeutics has a short interest ratio ("days to cover") of 9.04.

Change versus previous month

Short interest in Lexeo Therapeutics has recently decreased by 6.69%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lexeo Therapeutics does not currently pay a dividend.

Dividend Growth

Lexeo Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: N/A

News Sentiment

Lexeo Therapeutics has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

Search Interest

5 people have searched for LXEO on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Lexeo Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Lexeo Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,240.00 in company stock.

Percentage Held by Insiders

2.00% of the stock of Lexeo Therapeutics is held by insiders.

Percentage Held by Institutions

60.67% of the stock of Lexeo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/16/2026
• Chardan's 10th Annual Healthcare Conference: 10/20/2026
• Next Earnings (Estimated): 12/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LXEO
• Previous Symbol: NASDAQ:LXEO
• CIK: 1907108
• Web: www.lexeotx.com
• Phone: 212-547-9879
• Fax: N/A
• Employees: 59
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Lexeo Therapeutics: $16.43
• High Price Target: $25.00
• Low Price Target: $9.00
• Potential Upside/Downside: +522.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$99.96 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -41.85%
• Return on Assets: -38.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.89
• Quick Ratio: 13.89

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.38 per share
• Price / Book: 0.78

Miscellaneous

• Outstanding Shares: 82,050,000
• Free Float: 80,405,000
• Market Cap: $216.61 million
• Optionable: Not Optionable
• Beta: 1.63